SEC Form 4 · accession 0001258693-26-000010
Vaxcyte, Inc. · PCVX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Grant Pickering
Officer — CHIEF EXECUTIVE OFFICER · Director
Period of report
Jun 18, 2026
Accepted (ET)
Jun 18, 2026 · 8:08 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001649094
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 18, 2026 | M | 225 | $1.79 | A | 497,164 | D | |
| Common Stock | Jun 18, 2026 | S | 225 | $52.51 | D | 496,939 | D | |
| Common Stock | Jun 18, 2026 | S | 22,236 | $52.50 | D | 474,703 | D | |
| Common StockF2 | Jun 18, 2026 | S | 1,000 | $52.50 | D | 135,215 | I | By Children's Trust |
| Common StockF3 | Jun 18, 2026 | S | 1,000 | $52.50 | D | 135,215 | I | By Children's Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $1.79 | Jun 18, 2026 | M | 225 | D | — | May 17, 2027 | Common Stock | 225 | 0 | D |
Explanation of responses
- F1The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted March 3, 2026.
- F2Shares are held directly by a trust for the benefit of the Reporting Person's son.
- F3Shares are held directly by a trust for the benefit of the Reporting Person's daughter.
- F4Option is fully vested and exercisable.